Recap: Palisade Bio Q3 Earnings
Portfolio Pulse from Benzinga Insights
Palisade Bio (NASDAQ:PALI) reported Q3 earnings with an EPS of $-0.49, missing estimates by 44.12% compared to the expected $-0.34. Revenue was unchanged from the same period last year. Despite missing EPS last quarter, PALI's share price increased by 2.9% the following day.
November 10, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Palisade Bio reported a larger than expected loss per share for Q3, which could negatively impact investor sentiment and the stock price in the short term.
Earnings misses typically lead to negative investor sentiment, which can result in a decline in stock price. However, the previous quarter's miss was followed by a share price increase, indicating that market reactions can be unpredictable. The score reflects the general trend of negative impact due to an earnings miss, but with moderate confidence due to past market reaction.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100